Table of Content

Archive

Spring 2020, Vol. 28 No. 1

Hong Kong J. Dermatol. Venereol. (2020) 28, 11-16


Review Article

Cutaneous adverse effects of targeted therapies

標靶治療的皮膚不良反應

OC Lau 劉安祥

Abstract

Novel antineoplastic therapy has evolved and shifted to molecularly targeted agents. They are designed to block specific cancer cell processes. However, many of these agents, particularly those interfering with signal transduction (e.g., epidermal growth factor receptor [EGFR] inhibitors, multitargeted tyrosine kinase inhibitors [TKIs]), frequently cause cutaneous adverse events. The dermatological adverse reactions not only affect cosmetically, but may also lead to poor treatment adherence, dose reduction or even discontinuation of treatment. In this article, we will describe key clinical features of common dermatological adverse reactions among the common targeted therapies, focusing mainly on skin toxicity, as well as to discuss the pathology and suggested treatments for these reactions.

新型抗腫瘤治療已發展並轉向分子標靶性藥物。它們旨在阻止特定的癌細胞過程。然而當中不少,特別是那些通過干擾訊息傳遞的藥物(例如表皮生長因子受體抑製劑、多重標靶性酪氨酸激抑製劑)經常會引起皮膚不良反應。皮膚不良反應不僅影響儀容,而且可能減低治療依從性、或需調低劑量甚至停止治療。本文中,我們將描述常見標靶治療中常見皮膚不良反應的關鍵臨床特徵,主要聚焦在皮膚毒性上,並討論這些反應的病理和建議的治療方法。

Keywords: Cutaneous adverse reaction, epidermal growth factor inhibitors, multi-targeted tyrosine kinase inhibitors, targeted therapy

關鍵詞: 皮膚不良反應、表皮生長因子抑製劑、多重標靶性酪氨酸激抑製劑、標靶治療